(Q34027512)

30 July 2017

1 reference

title

Therapeutic implications of escape from angiotensin-converting enzyme inhibition in patients with chronic heart failure (English)

1 reference

30 July 2017

1 reference

chronic heart failure

1 reference

P V Ennezat

1

1 reference

30 July 2017

M Berlowitz

series ordinal

2

1 reference

30 July 2017

E H Sonnenblick

series ordinal

3

1 reference

30 July 2017

T H Le Jemtel

series ordinal

4

1 reference

30 July 2017

language of work or name

1 reference

1 May 2000

1 reference

Current cardiology reports

30 July 2017

published in

1 reference

30 July 2017

volume

2

1 reference

30 July 2017

issue

3

1 reference

30 July 2017

page(s)

258-262

1 reference

Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11886-000-0077-3

Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-000-0077-3

Cardiovascular death and left ventricular remodeling two years after myocardial infarction: baseline predictors and impact of long-term use of captopril: information from the Survival and Ventricular Enlargement (SAVE) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-000-0077-3

Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-000-0077-3

Additive Effects of Combined Angiotensin-Converting Enzyme Inhibition and Angiotensin II Antagonism on Blood Pressure and Renin Release in Sodium-Depleted Normotensives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-000-0077-3

Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-000-0077-3

Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-000-0077-3

Survival after myocardial infarction in the rat. Role of tissue angiotensin-converting enzyme inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-000-0077-3

How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure?

21 January 2018

1 reference

12 December 2020

Angiotensin II formation in dog heart is mediated by different pathways in vivo and in vitro

1 reference

12 December 2020

Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor

1 reference

12 December 2020

Angiotensin converting enzyme inhibition, AT1 receptor inhibition, and combination therapy with pacing induced heart failure: effects on left ventricular performance and regional blood flow patterns.

1 reference

12 December 2020

Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group

1 reference

12 December 2020

Compartmentalization of angiotensin II generation in the dog heart. Evidence for independent mechanisms in intravascular and interstitial spaces

1 reference

12 December 2020

Regulation of local angiotensin II formation in the human heart in the presence of interstitial fluid. Inhibition of chymase by protease inhibitors of interstitial fluid and of angiotensin-converting enzyme by Ang-(1-9) formed by heart carboxypeptid

1 reference

12 December 2020

Angiotensin AT1 receptor inhibition, angiotensin-converting enzyme inhibition, and combination therapy with developing heart failure: cellular mechanisms of action

1 reference

12 December 2020

Synergistic effects of combined converting enzyme inhibition and angiotensin II antagonism on blood pressure in conscious telemetered spontaneously hypertensive rats

1 reference

12 December 2020

Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group

1 reference

12 December 2020

Induction of Angiotensin I-Converting Enzyme by Captopril in Cultured Human Endothelial Cells*

1 reference

12 December 2020

Angiotensin II-receptor blockade further reduces afterload safely in patients maximally treated with angiotensin-converting enzyme inhibitors for heart failure

1 reference

12 December 2020

Enalapril and losartan reduced cardiac mass and improved coronary hemodynamics in SHR

1 reference

12 December 2020

Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure

1 reference

12 December 2020

Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions

1 reference

12 December 2020

Angiotensin II formation in the intact human heart. Predominance of the angiotensin-converting enzyme pathway

1 reference

12 December 2020

Functional and biochemical analysis of angiotensin II-forming pathways in the human heart

1 reference

12 December 2020

Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure

1 reference

12 December 2020

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

1 reference

12 December 2020

Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure

1 reference

12 December 2020

10.1007/S11886-000-0077-3

Identifiers

DOI

1 reference

Dimensions Publication ID

30 July 2017

1045737456

0 references

1 reference